The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1.
about
Development of Orally Active Thrombin Inhibitors for the Treatment of Thrombotic Disorder DiseasesThrombostatin FM compounds: direct thrombin inhibitors - mechanism of actionin vitroandin vivoRational Design and Characterization of D-Phe-Pro-D-Arg-Derived Direct Thrombin InhibitorsPlatelet-derived S100 family member myeloid-related protein-14 regulates thrombosis.Endothelial Kruppel-like factor 4 protects against atherothrombosis in miceDeletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosisThe thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 (KLF2).Leukocyte integrin Mac-1 regulates thrombosis via interaction with platelet GPIbα.Tissue factor, blood coagulation, and beyond: an overview.Critical role for Syk in responses to vascular injury.Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin.Mapping human protease-activated receptor 4 (PAR4) homodimer interface to transmembrane helix 4Effect of adenosine A2 receptor stimulation on platelet activation-aggregation: differences between canine and human models.Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage siteAntithrombotic Effects of Nur77 and Nor1 Are Mediated Through Upregulating Thrombomodulin Expression in Endothelial Cells.Targeting the anionic region of human protease-activated receptor 4 inhibits platelet aggregation and thrombosis without interfering with hemostasis.Mapping the interaction of bradykinin 1-5 with the exodomain of human protease activated receptor 4.
P2860
Q26827986-E969D8E2-1C79-41C2-AEEF-AFFCC5BCEC31Q27649983-FDB5EFC1-6A8A-4969-B233-93CE7737C7C7Q27678254-5BDBA44C-75FF-40F5-927B-A86685843140Q28512072-FD753F76-B6AC-4020-9FF0-E73B25D66071Q30423011-F9A6FA3F-F304-4A5F-A285-C879FF636B72Q33305420-6D44B3F9-93D5-45AB-B8B4-715B375E0541Q33749676-D0BBAED3-65DE-4F93-A409-D21C0619D87EQ33815771-C8D03D6B-8B47-4A04-A4AE-B3A2E2743F15Q35222618-6FBFF475-92F1-4735-ACD3-E1ABBE207721Q35525691-8E8BB8D0-3083-44B9-B057-5E3DD5A6A51DQ35849803-88F5A2BB-CA42-4B50-B3CF-43F3D2720376Q35879995-037E888E-471E-4EC2-8FC4-A76ADE468AE1Q36593731-74AEB1B7-3A78-4039-B1DC-3125D37F8B29Q36908851-4338604A-E044-43F3-A811-8D070151E27CQ37419860-49741674-05DF-447B-B3F7-443EBC5E8D8BQ41810106-8A5B49B1-6CCB-4FD2-8DB4-6D6B722FA8EBQ45202849-04FE33E2-CA6E-4DC6-8AA8-A02FF5494688
P2860
The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The preparation and characteri ...... protease-activated receptor 1.
@ast
The preparation and characteri ...... protease-activated receptor 1.
@en
type
label
The preparation and characteri ...... protease-activated receptor 1.
@ast
The preparation and characteri ...... protease-activated receptor 1.
@en
prefLabel
The preparation and characteri ...... protease-activated receptor 1.
@ast
The preparation and characteri ...... protease-activated receptor 1.
@en
P2093
P356
P1476
The preparation and characteri ...... protease-activated receptor 1.
@en
P2093
Ahmed A K Hasan
Alvin H Schmaier
Benedict R Lucchesi
Fakhri Mahdi
Laine J Murphey
Mark Warnock
Marvin T Nieman
Nancy J Brown
P304
P356
10.1124/JPET.104.069229
P407
P577
2004-06-21T00:00:00Z